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PURPOSE. We studied associations of genetic polymorphisms in age-related maculopathy
susceptibility 2 (ARMS2) and complement factor H (CFH) in nonagenarians with age-related
macular degeneration (AMD).
METHODS. This case-control study comprised 2737 persons (1204 controls, 1433 AMD cases),
including 166 nonagenarians (52 controls, 114 AMD cases). Single nucleotide polymorphisms
(SNPs) in the genes ARMS2 and CFH were determined. Risk scores were computed by
multiple logistic regression analysis, including genetic and environmental risk factors
(smoking, hypertension, body mass index, diabetes) for different age groups (<70, 70–79,
80–89, ‡90 years [nonagenarians]).
RESULTS. In nonagenarians, ARMS2 showed the weakest associations with AMD (odds ratio
[OR] ¼ 1.52, P¼ 0.127) compared to the other groups (OR, 70 years ¼ 2.23, P¼ 1.033 1013;
OR, 70–79 years ¼ 2.70, P ¼ 1.00 3 1013; OR, 80–89 years ¼ 3.11, P ¼ 6.56 3 108). For
CFH, ORs for AMD increased with age (<70 years OR ¼ 1.96, P¼ 1.803 1011; 70–79 years OR
¼ 1.89, P¼ 4.483 1013; 80–89 years OR ¼ 2.71, P¼ 1.283 107), but decreased again in the
nonagenarians (OR ¼ 2.21, P¼ 0.005). Compared to the group <70 years, reduced minor allele
frequencies (MAFs) for AMD patients were observed in the nonagenarians (CFH 0.54 vs. 0.43, P
¼ 0.009; ARMS2 0.44 vs. 0.29, P ¼ 2.97 3 105), while the MAFs in controls were not
significantly different. The genetic risk score revealed the lowest discriminative power in the
nonagenarians with an area-under-curve (AUC) of 0.658 for receiver-operating characteristics
(AUC 80–89 years ¼ 0.768, 70–79 years ¼ 0.704, <70 years ¼ 0.682), while no significant
difference was seen for the environmental risk score (AUC < 70 years ¼ 0.579, 70–79 years ¼
0.567, 80–89 years ¼ 0.600, >90 years ¼ 0.608).
CONCLUSIONS. Risk alleles in CFH and ARMS2 have a significantly smaller effect on AMD
development in nonagenarians, while environmental factors retain a similar effect.
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Age-related macular degeneration is one of the mostcommon age-related diseases and the leading cause of
severe vision impairment in developed countries. Vision loss
occurs mostly in advanced stages. either due to geographic
atrophy of the retinal pigment epithelium or due to neovascular
AMD with the formation of choroidal neovascularization (CNV).
Although the etiology of AMD is known to be multifactorial,
involving a complex interaction between genetic predisposi-
tion and environmental factors, such as age, cigarette smoking,
body mass index (BMI), diabetes, and hypertension,1–8 the
genetic variants associated with AMD account for approximate-
ly 70% of the risk for the condition.9,10 Hence, substantial effort
has been made in understanding the genetics of AMD by
identifying several AMD susceptibility loci over the past years.
The two major loci were identified at chromosomes 1q31 and
10q26. These two loci explain approximately half of the
heritability of AMD.11 They involve variants in the complement
factor H (CFH) gene, the main regulator of the alternative
complement pathway,12 and polymorphisms on chromosome
10q26 encompassing the age-related maculopathy susceptibil-
ity 2 (ARMS2) gene,13 and the adjacent high-temperature
requirement factor A1 (HTRA1) gene,14 which may alter the
integrity of Bruch’s membrane.15 Age is of high importance in
the pathogenesis of AMD, with a prevalence of AMD in
nonagenarians of almost 60%.16 Although genetic studies
adjusted for age as a confounder, most studies had only low
numbers of very old participants aged over 90 years.
In this study, the impact of genetic associations and
environmental influences in nonagenarian AMD patients in
comparison with other age groups was investigated. For this
purpose, four different age groups (<70, 70–79, and 80–89
years, and nonagenarians) were analyzed for risk variants in
CFH and ARMS2, and known environmental risk factors, such
as hypertension, BMI, cigarette smoking, and diabetes mellitus.
PATIENTS AND METHODS
Study Population
The current study was part of the European Genetic Database
(EUGENDA, available in the public domain at www.eugenda.
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org), and included 166 nonagenarian persons (147 from
Cologne area, 19 from Nijmegen area) and 2571 persons aged
between 50 and 89 years (984 persons < 70 years, 1099
persons aged 70–79 years, 488 persons aged 80–89 years; 1218
from Cologne, 1353 from Nijmegen). EUGENDA is a German-
Dutch database for AMD patients and healthy control
individuals, and comprises more than 4000 phenotyped cases.
For the recruitment of nonagenarians, 1500 persons of 5314
aged 90 years and older from the registry of the city of Cologne
were chosen by random and contacted once by mail. No
information except their age was available for contacted
persons and for the persons not participating in this study.16
All participants gave written consent before inclusion in the
study. From all participants peripheral blood samples were
collected, and detailed information about medical history, and
dietary and life-style habits, such as smoking, were document-
ed through a questionnaire. Retinal imaging was performed
using color fundus photography (FP) of Field 2 (Cologne:
Canon UVI fundus camera; Canon, Tokyo, Japan, and
Nijmegen: Topcon TRC 50IX fundus camera; Topcon, Tokyo,
Japan). Spectral-domain optical coherence tomography (SD-
OCT; Spectralis HRA system; Heidelberg Engineering, Heidel-
berg, Germany) and fluorescein angiography (FA) images were
evaluated additionally if available.
Collection of data was performed in accordance with the
tenets of the Declaration of Helsinki and the Medical Research
Involving Human Subjects Act (WMO) and approved by the
local ethics committees of the participating centers at Cologne
and Nijmegen.
AMD Staging
Age-related macular degeneration staging was performed by
grading of retinal images according to the standard protocol of
the Cologne Image Reading Center (CIRCL) by certified
graders. Age-related macular degeneration was classified by
the presence of pigmentary changes together with at least 10
small drusen (<63 lm) or presence of intermediate (63–124
lm, early AMD) or the presence of large drusen (‡125 lm
diameter) or ‡15 intermediate drusen or geographic atrophy
secondary to AMD outside the foveal central subfield (FCS,
intermediate AMD) in the Early Treatment Diabetic Retinopa-
thy Study (ETDRS) grid on FP. The subgroup of late AMD was
defined as either AMD with geographic atrophy inside the FCS
and/or CNV in at least one eye. Geographic atrophy was
defined as sharply demarcated round or oval areas of
depigmentation of the RPE of ‡175 lm diameter with
increased visibility of choroidal vessels on FP without signs
of CNV. Late AMD with CNV was defined as CNV lesion within
the ETDRS grid secondary to AMD either on FP, FA, or SD-OCT,
when there was evidence for fluid, blood, or fibrovascular
tissue on FP, active classic or occult CNV, or signs for previous
CNV, such as staining scar on FA and/or subretinal hyper-
reflective material, or fibrovascular pigment epithelial detach-
ment (PED) on SD-OCT secondary to AMD.
Control subjects had to have no drusen, or only small
drusen or pigmentary changes without or with less than 10
small drusen.
Genotyping
Genotyping of single nucleotide polymorphisms (SNPs) in the
CFH (Y402H; rs1061170) and ARMS2 (A69S; rs10490924) gene
was performed with a pre-designed TaqMan SNP genotyping
assay for ARMS2 (Assay ID C_29934973_20, Applied Biosys-
tems, Foster City, CA) and a custom TaqMan SNP genotyping
assay for CFH (Applied Biosystems). The assays were analyzed
on the ABI 7900HT system (Applied Biosystems) according to
the protocols provided by the manufacturer.
Statistical Analysis
All calculations were carried out using SPSS software version
21.0 (IBM Software and Systems, Armonk, NY). Genetic
associations of CFH and ARMS2 with AMD risk were assessed
by logistic regression analysis. Genotypes were coded as the
number of AMD risk alleles (0, 1, and 2). For the logistic
regression analyses of environmental factors, we included
smoking (ever/never smoker), hypertension, diabetes, BMI
(normal/overweight/obese), and sex. Odds ratios (OR) and
95% confidence intervals (CI) were calculated for genetic risk
alleles and environmental risk factors in unadjusted and
adjusted models. Based on the stepwise logistic regression
for genetic and environmental factors, risk scores were
calculated with three logistic regression equations:
logit ðp1Þ ¼ log ðp1= 1  p1½ Þ ¼ b0 þ b1*ARMS2
þ b2*CFH;
where p1 ¼ risk for AMD under genetic influence;
logit ðp2Þ ¼ logðp2= 1  p1½ Þ ¼ b0 þ b1*smoking
þ b2*hypertension þ b3*BMI þ b4*diabetes
þ b5*sex;
where p2 ¼ risk for AMD under environmental influence; and
logit ðp3Þ ¼ logðp3= 1  p3½ Þ ¼ b0 þ b1*ARMS2 þ b2*CFH
þ b1*smokingþ b2*hypertension
þ b3*BMI þ b4*diabetesþ b5*sex;
where p3 ¼ risk for AMD under genetic and environmental
influence.
An estimate for the probability of AMD for each risk score
was calculated with the equation P ¼ exp(logit[P])/




This study included 2737 persons. The nonagenarian group
included 166 persons with at least 90 years of age (92.76 6
2.46 years; range, 90–100 years). Characteristics of all age
groups are summarized in Table 1.
Associations of ARMS2 and CFH With AMD in
Different Age Groups
Associations with AMD were determined for the SNPs
rs10490924 in ARMS2 and rs1061170 in CFH for different
age groups using logistic regression analysis (Table 2).
The weakest association for ARMS2 was observed in the
group of nonagenarians. Similarly, the association of CFH with
AMD (and late AMD) increased continuously from the youngest
group to the group of ‘‘80–89 years’’ and dropped down for
persons aged more than 90 years.
An additional analysis adjusting for sex, site, smoking,
hypertension, BMI, and diabetes yielded similar results (Table 3).
Different Discriminative Ability of Computed Risk
Scores for Different Age Groups
Based on genetic risk alleles and environmental factors, three
multiple logistic regression models were generated. In the first
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model risk alleles of the two SNPs in CFH and ARMS2 were
used as predictive variables to compute genetic risk scores for
each individual (model 1). An environmental risk score was
calculated in a similar fashion (model 2). A general risk score
was generated from all genetic and environmental factors
(model 3, Table 4).
The highest classification efficiency in model 1 was
observed in the group ‘‘80–89 years’’ (area-under-curve
[AUC] ¼ 0.768 for AMD versus No AMD, AUC ¼ 0.797 for late
AMD versus No AMD) and diminished in the nonagenarian
group (AUC¼ 0.659 for AMD versus No AMD, AUC¼ 0.717 for
late AMD versus No AMD). Analysis of only environmental risk
score (model 2) showed poor classification efficiency for all
age groups and the combined model 3 revealed similar results
to model 1 with only marginally better classification.
Differences of Genetic Associations Within
Different Age Groups
The Figure presents the minor allele frequencies (MAFs) in
different age groups.
For both SNPs, there was a decrease of MAFs with
increasing age in controls and AMD subgroups (AMD and late
AMD), especially visible in the comparison of ‘‘80–89 years’’
with nonagenarians. The only exceptions for this pattern were
the MAFs of ARMS2 in controls: the MAFs were highest in the
TABLE 1. Demographics
<70 y 70–79 y 80–89 y Nonagenarians
No AMD AMD No AMD AMD No AMD AMD No AMD AMD
n 669 315 496 603 87 401 52 114
Sex (n/%)
Female 398/40.5% 189/60.0% 274/55.2% 357/59.2% 46/52.9% 257/64.1% 35/67.3% 76/66.7%
Male 271/59.5% 126/40.0% 222/44.8% 246/40.8% 41/47.1% 144/35.9% 17/32.7% 38/33.3%
Mean age 6 SD 64.68 6 4.13 65.06 6 3.77 73.48 6 2.76 74.72 6 2.87 82.58 6 2.42 83.25 6 2.61 92.96 6 2.26 92.66 6 2.55
Site (n/%)
UK 335/50.1% 135/42.9% 235/47.4% 284/47.1% 38/43.7% 191/47.6% 49/94.2% 98/86.0%
UMCN 334/49.9% 180/57.1% 261/52.6% 319/52.9% 49/56.3% 210/52.4% 3/5.8% 16/14.0%
Smoking 385/59.3% 177/56.2% 271/54.6% 321/60.9% 41/50.0% 158/50.0% 24/46.2% 43/42.2%
Hypertension 231/35.1% 97/33.1% 211/43.1% 203/35.7% 38/44.7% 104/29.0% 28/54.9% 46/40.4%
Diabetes 45/6.8% 22/7.5% 42/8.6% 67/11.8% 7/8.2% 33/9.2% 4/7.8% 14/12.8%
BMI
<25 276/44.0% 99/36.8% 158/34.4% 189/36.1% 29/37.2% 130/40.6% 23/53.5% 57/59.4%
25–29.9 258/41.1% 121/45.0% 235/51.2% 256/48.9% 40/51.3% 150/46.9% 17/39.5% 34/35.4%
‡30 93/14.8% 49/18.2% 66/14.4% 78/14.9% 9/11.5% 40/12.5% 3/7.0% 5/5.2%
UK, University Hospital of Cologne, Germany; UMCN, The Radboud University Nijmegen, the Netherlands.
FIGURE. Minor allele frequencies of CFH and ARMS2 in different age groups and different AMD stages. Minor allele frequencies are compared using v2
test. P values of the v2 test comparing ‘‘<70 years’’ with ‘‘nonagenarians’’ are presented as P1 for no AMD cases, P2 for AMD cases, and P3 for late AMD
cases.
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youngest group (0.25), decreasing to 0.19 in the group of ‘‘80–
89’’ years and in the nonagenarian group (0.20)
The OR for the nonagenarian group (nonagenarian versus
nonnonagenarian) was estimated 0.74 for CFH (P¼ 0.085; 95%
CI, 0.53–1.04) and 0.61 for ARMS2 (P ¼ 0.007; 95% CI, 0.43–
0.87) using a logistic regression model adjusting for AMD
status, sex, smoking, hypertension, diabetes, and BMI.
DISCUSSION
In this study we analyzed the age-dependent association of
genetic and environmental risk factors for AMD, and compared
very old persons aged 90–100 years with different age groups.
While the associations for the two major genetic risk factors
ARMS2 (rs10490924) and CFH (rs1061170) were strong in
persons aged less than 90 years with continuously rising OR
pattern from the youngest group to the group of ‘‘80–89
years,’’ this association was much weaker for the nonagenarian
group. We also found significantly reduced risk allele
frequencies in nonagenarians compared to the youngest group
for the AMD phenotype, although the risk allele frequencies in
controls remained relatively stable without significant differ-
ence. These findings were supported by risk score calculations
using logistic regression analysis, demonstrating that CFH and
ARMS2 risks alleles have a weaker role in AMD at very
advanced age. In addition, no difference in environmental
factors was observed between nonagenarians and younger
AMD patients. This suggested that other genetic and environ-
mental factors may be involved in the development of AMD in
this age group. In addition, one can speculate that risk alleles in
CFH and ARMS2 are associated with increased mortality.
TABLE 3. Associations of ARMS2 and CFH With AMD in Different Age Groups in an Adjusted Model
AMD vs. No AMD Adjusted* Late vs. No AMD Adjusted*
OR P Value 95% CI OR P Value 95% CI
ARMS2
<70 y 2.14 7.39 3 1012 1.720–2.655 3.77 1.01 3 1013 2.738–5.195
70–79 y 2.73 1.00 3 1013 2.197–3.393 3.67 1.00 3 1014 2.835–4.759
80–89 y 2.85 2.67 3 106 1.839–4.403 3.36 2.12 3 107 2.125–5.310
Nonagenarians 1.39 0.293 0.754–2.541 2.35 0.018 1.160–4.749
CFH
<70 y 1.83 1.95 3 108 1.481–2.257 2.63 6.99 3 1010 1.932–3.567
70–79 y 1.90 9.74 3 1012 1.578–2.281 3.22 1.00 3 1013 2.529–4.094
80–89 y 2.92 5.17 3 107 1.920–4.430 3.51 5.28 3 108 2.233–5.517
Nonagenarians 2.34 0.008 1.250–4.368 2.38 0.013 1.197–4.742
* Adjusted model with covariates smoking, hypertension, diabetes, body mass index, site, and sex.
TABLE 2. Associations of ARMS2 and CFH With AMD in Different Age Groups
AMD vs. No AMD Late AMD vs. No AMD
OR P Value 95% CI OR P Value 95% CI
ARMS2
<70 y 2.23 1.03 3 1013 1.83–2.73 3.34 1.00 3 1013 2.55–4.40
70–79 y 2.70 1.00 3 1013 2.22–3.29 3.58 1.00 3 1013 2.84–4.50
80–89 y 3.11 6.56 3 108 2.06–4.71 3.63 2.75 3 109 2.37–5.55
Nonagenarians 1.52 0.127 0.89–2.62 2.40 0.004 1.31–4.37
CFH
<70 y 1.96 1.80 3 1011 1.61–2.38 2.76 6.68 3 1013 2.10–3.64
70–79 y 1.89 4.48 3 1013 1.59–2.24 2.87 1.00 3 1013 2.33–3.56
80–89 y 2.71 1.28 3 107 1.87–3.93 2.97 2.87 3 108 2.02–4.36
Nonagenarians 2.21 0.005 1.28–3.82 2.34 0.004 1.31–4.17
TABLE 4. Discrimination Accuracy of Genetic and Environmental Risk Scores
AUC for Discrimination AMD vs. No AMD AUC for Discrimination Late AMD vs. No AMD
Genetic RS* Environmental RS† General RS‡ Genetik RS Environmental RS General RS
<70 y 0.682 0.579 0.689 0.768 0.608 0.801
70–79 y 0.704 0.567 0.714 0.784 0.603 0.809
80–89 y 0.768 0.600 0.787 0.797 0.618 0.825
Nonagenarians 0.659 0.608 0.682 0.717 0.666 0.742
RS, risk score.
* Genetic RS based on multivariate logistic regression, including ARMS2 and CFH.
† Environmental RS based on multiple logistic regression, including hypertension, diabetes, body mass index, smoking, diabetes, site, sex.
‡ General RS based on multivariate logistic regression, including environmental and genetic factors.
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A similar age-dependent association of CFH was described
previously by Adams et al.17 where the prevalence of AMD in
persons homozygous for the CFH risk variant was decreased in
older persons (age range from 48–86 years). Grassmann et al.18
also reported relatively lower associations of 13 AMD risk
variants with AMD in an elderly group (>75 years) in
comparison with a younger group (<75 years). The phenom-
enon of genetic differences between younger and older
populations is widely described in longevity studies and
explained as a result of differential survival, with an
enrichment of ‘‘longevity genes’’ in the elderly.19–21 Lower
effect sizes (ORs) of genetic risk alleles in ARMS2 and CFH on
the development of AMD, and lower risk allele frequencies in
nonagenarian AMD patients may be caused by increased
mortality of AMD patients carrying these alleles. Differential
survival by AMD has been investigated in other studies. Some
found an increased mortality risk in persons with AMD,7,22,23
while others did not find this association.24–26 The AREDS
Report No. 13 showed an association of AMD with increased
mortality even after adjustment for potentially important
covariates.7 In contrast, in the Rotterdam Study, shorter
survival of AMD patients was explained by systemic risk
factors also affecting mortality: There was no significant
association of AMD with mortality after adjustment for various
systemic factors.24 The CFH risk variant could be associated
with an increased mortality27 by its reduced capacity to
downregulate complement activation and control inflamma-
tion.28 In a longitudinal study of nonagenarians, increased
mortality was observed among the carriers of the CFH
rs1061170 allele independent of comorbidities.27
The results presented here are based on a case-control
study, and, thus, do not allow the analysis of longitudinal or
epidemiologic parameters. Our study included a large nonage-
narian group, who primarily came from a small area in
Germany, which may increase the chance of a selection bias,
especially as a bias toward more healthy and mobile
nonagenarians is possible. Furthermore, our analysis was
limited to two genetic polymorphisms and few environmental
factors. An extended analysis including other genetic and
environmental factors may identify effects that explain AMD in
the nonagenarian population. It must be noted that environ-
mental factors may change over time as well. Therefore, the
nonagenarian group cannot be matched easily with younger
populations. For example, it is unknown what time span in life
influences AMD development. The allele frequencies and
effect sizes of ARMS2 and CFH SNPs in the younger group
were comparable to those in other studies.18,23,29
In summary, in our study genetic risk alleles in CFH and
ARMS2 showed significantly smaller effect on AMD develop-
ment in nonagenarians, while environmental factors retained a
similar effect in advanced age. Larger epidemiologic studies
with more statistical power are needed to investigate the role
of CFH and ARMS2 in nonagenarians and to validate our
results. The verification of the enrichment of nonrisk allele
frequencies of CFH and ARMS2 in a long-lived population may
indicate a genetic influence of CFH and ARMS2 on mortality.
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